- Home
- IMRN vs RDHL Comparison
IMRN vs RDHL Comparison
Compare IMRN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- RDHL
- Stock Information
- Founded
- IMRN 1994
- RDHL 2009
- Country
- IMRN Australia
- RDHL Israel
- Employees
- IMRN N/A
- RDHL N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- RDHL Health Care
- Exchange
- IMRN Nasdaq
- RDHL Nasdaq
- Market Cap
- IMRN 15.0M
- RDHL 13.1M
- IPO Year
- IMRN N/A
- RDHL N/A
- Fundamental
- Price
- IMRN $2.69
- RDHL $8.16
- Analyst Decision
- IMRN Strong Buy
- RDHL
- Analyst Count
- IMRN 1
- RDHL 0
- Target Price
- IMRN $5.00
- RDHL N/A
- AVG Volume (30 Days)
- IMRN 5.6K
- RDHL 40.1K
- Earning Date
- IMRN 10-15-2024
- RDHL 10-15-2024
- Dividend Yield
- IMRN N/A
- RDHL N/A
- EPS Growth
- IMRN N/A
- RDHL N/A
- EPS
- IMRN N/A
- RDHL N/A
- Revenue
- IMRN $3,271,194.00
- RDHL $3,707,000.00
- Revenue This Year
- IMRN N/A
- RDHL $224.90
- Revenue Next Year
- IMRN N/A
- RDHL $82.69
- P/E Ratio
- IMRN N/A
- RDHL N/A
- Revenue Growth
- IMRN 171.67
- RDHL N/A
- 52 Week Low
- IMRN $1.48
- RDHL $6.43
- 52 Week High
- IMRN $5.96
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- IMRN 51.76
- RDHL 40.13
- Support Level
- IMRN $2.66
- RDHL $7.95
- Resistance Level
- IMRN $2.87
- RDHL $9.05
- Average True Range (ATR)
- IMRN 0.11
- RDHL 0.61
- MACD
- IMRN 0.00
- RDHL -0.20
- Stochastic Oscillator
- IMRN 54.85
- RDHL 6.73
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.